Author | Lyudmila Bazhenova, MD | OncLive

Author | Lyudmila Bazhenova, MD


Dr. Bazhenova on the Potential Approval of Lorlatinib for Patients With ALK-Positive NSCLC

May 07, 2018

Lyudmila Bazhenova, MD, professor of clinical medicine, University of California, San Diego, discusses the potential approval of lorlatinib for patients with ALK-positive non–small cell lung cancer (NSCLC).